Pharma.AI Fall 2026 Release Recap: Transforming Drug Discovery and Development Through Specialized Models and AI Agents
en-GBde-DEes-ESfr-FR

Pharma.AI Fall 2026 Release Recap: Transforming Drug Discovery and Development Through Specialized Models and AI Agents

14/10/2026 Insilico Medicine

Insilico has a connected set of capabilities for adapting AI to scientific work. MMAI Gym develops specialized models; benchmarking helps researchers assess their performance; Generative Biologics, Chemistry42, and PandaOmics provide scientific tools; and MCP connects those tools to AI assistants. The practical value is a path from scientific specialization to research workflows that teams can inspect and direct.

MMAI Gym turns foundation models into scientific specialists

MMAI Gym for Science is Insilico’s scientific post-training and evaluation framework. Post-training means taking a model that has already learned general capabilities and further adapting it to defined scientific tasks. The Gym uses scientific data, reasoning examples, and domain-focused training to develop models that can work on problems in drug discovery and development.
This gives the company both a framework for improving models and a family of specialists built for particular scientific jobs. The five specialists shown in the webinar serve different decisions in a discovery program:

  • Kinase activity prediction estimates compound activity against kinases, helping researchers compare compounds within this important family of biological targets.
  • GPCR activity prediction assesses compound activity across G protein-coupled receptors, supporting lead prioritization and receptor selectivity assessment.
  • ADMET prediction estimates properties relating to absorption, distribution, metabolism, excretion, and toxicity, helping teams assess compound behavior before further testing.
  • Single-step retrosynthesis proposes possible chemical precursors for a synthesis step, supporting chemists as they consider how a molecule could be made.
  • Therapeutic target discovery helps prioritize biological targets for investigation in a disease, supporting the decision about where a discovery program should focus.


The reported results show why specialization matters. Insilico described performance matching or exceeding the state of the art across more than 70 chemistry and biology benchmark tasks. In the ADMET demonstration, InsilicoMMAI-4B-Chem-ADMET competed with established specialist methods and showed lower prediction error on several displayed endpoints. These are examples of task-specific scientific performance.

Evaluation makes model performance useful to researchers

DDD Benchmark provides a common setting for comparing general-purpose models and scientific specialists using consistent datasets, splits, and metrics. Researchers can examine results by scientific domain and individual task, so a model’s strengths can be considered in relation to the work they need it to do. The company reported 302 benchmarks across six R&D domains.

The O3DC complements this with an open index of benchmarks, their scope, and their known caveats. It helps the community assess whether a benchmark is suitable for a scientific question. The benchmarking service described in the webinar also lets teams assess their own models through a protected endpoint, receive private reports, and retain the model in their own environment.

The compact Liquid model

LFM2-2.6B-MMAI, developed with Liquid AI, is a compact chemistry model built through the Gym. The company presented it as available for direct testing, with efficient on-premise deployment and state-of-the-art performance on selected tasks. Its 2.6-billion-parameter size matters because teams can consider a smaller scientific model for their own infrastructure, where deployment requirements and data control are important. It is a separate model from the 4B ADMET specialist shown in the comparisons.

The Virtual Aging Cell

The Virtual Aging Cell is an age-aware, multi-agent simulation platform for exploring how an intervention may affect human biological systems. The company described a system, orchestrating of specialist agents working within a shared causal graph across molecular, cellular, tissue, systemic, and phenotype levels. Specialized agents consult scientific literature and clinical databases, then connect proposed effects across these levels while retaining the evidence and reasoning behind each connection.

Generative Biologics: Epitope reasoning and MCP connectors

Generative Biologics provides tools for designing, predicting properties of, and refining antibodies, nanobodies, and peptides. The new Epitope Prediction workflow addresses a practical question after a binder has been identified: where is it likely to interact with its target? It returns ranked predicted binding regions and inspectable structural models, giving researchers hypotheses they can compare and investigate.

Its MCP demonstration showed an agent evaluating existing antibody variants and preparing a shortlist for experimental validation based on the developability properties. The value is a clearer basis for choosing what to test next, with predictions, visualizations, and downloadable results available for review. The scientific output remains a computational recommendation until tested experimentally.

Chemistry42 connects molecular design with synthetic route planning

Chemistry42 combines generative AI and physics-based methods for small-molecule research. It brings molecular generation, property assessment, synthesis planning, and further calculations into one environment. Typed Excluded Volumes gives researchers spatial controls to guide molecular design according to their scientific hypothesis.

ChemCensor adds chemical-plausibility assessment to Retrosynthesis, the process of working backward from a desired molecule to possible ways to make it. It evaluates support from documented synthetic precedents, helping chemists scrutinize proposed routes. On the 100-target URSA-expert-2026 benchmark, the company reported a 55% Solv-2 score for Chemistry42 Retrosynthesis plus ChemCensor, compared with 32% for RetroChimera MCTS and 29% for AiZynthFinder MCTS. This is a result for a defined computational route-planning benchmark.

PandaOmics turns biological data into structured analysis

PandaOmics connects omics and biomedical data with target discovery and drug program evaluation. Its Agent is now the default interface described in the webinar: researchers can state a question in plain language and receive an analysis with supporting evidence. The new skills address three related research needs:

  • Single-Cell Signature compares gene expression across cell types and disease states, making biological differences easier to examine.
  • Indication Prioritization brings together disease rankings, biological rationale, genetic evidence, and the drug and clinical-trial landscape in a structured report.
  • CADD Structural Review assesses a target’s structural druggability and tractability, helping researchers consider its potential for structure-based discovery.


Additionally, PandaOmics Classic introduces Score Weights in TargetID, enabling researchers to adjust how evidence contributes to target rankings. Saving these preferences and including them in CSV exports makes the basis for a ranking easier to retain and explain.

MCP connects the scientific engines to AI assistants

Model Context Protocol, or MCP, provides a connection through which an AI assistant can call software tools. In Pharma.AI, it lets compatible clients such as Codex, Claude Code, and Cursor access the scientific platforms. Researchers describe a task; the agent coordinates tool calls and returns the results into the conversation for review and follow-up work.

The Chemistry42 demonstration linked molecule generation, profiling, candidate selection, and further calculations while retaining project context and allowing configuration review. This illustrates how scientific tasks can follow one another without manually rebuilding the workflow at each step. The platform tools perform the specialist work; the assistant coordinates it.

14/10/2026 Insilico Medicine
Regions: Asia, Hong Kong, North America, United States
Keywords: Applied science, Artificial Intelligence

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement